IP Library Granted Patent US 9,890,395
Granted Patent B2
US 9,890,395 · App. 15/080,101 · Granted Feb 13, 2018

Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT8) gene expression

Inventors: Trevor Collingwood (Novato, CA); Gregory J. Cost (Piedmont, CA)
Assignee: Sangamo Therapeutics, Inc.
C12N15/907C07K14/4703C07K16/00C12N9/1051C12N15/85C12N15/87C12P21/00C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,890,395
App. No.
15/080,101
Granted
Feb 13, 2018
Kind
B2
Abstract

Disclosed herein are methods and compositions for inactivating a FUT8 gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.

Claims (33)

1. A method of producing an antibody in an isolated cell, the method comprising:

inactivating an endogenous cellular FUT8 gene in an isolated cell by introducing one or more nucleic acids encoding first and second zinc finger nucleases, each zinc finger nuclease comprising a cleavage domain and a zinc finger protein, wherein the at least one of the zinc finger nucleases comprises a zinc finger DNA-binding domain comprising four, five or six zinc finger recognition regions ordered F1 to F4, F1 to F5 or F1 to F6 from N-terminus to C-terminus, and wherein F1 to F4, F1 to F5 or F1 to F6 comprise amino acid sequences as follows:

(i) F1: QSSDLSR (SEQ ID NO:9);

F2: TSGNLTR (SEQ ID NO:10);

F3: RSDDLSK (SEQ ID NO:11); and

F4: DRSALAR (SEQ ID NO:12);

(ii) F1: RSDVLSA (SEQ ID NO:14);

F2: QNATRIN (SEQ ID NO:15);

F3: DRSNLSR (SEQ ID NO:16); and

F4: RLDNRTA (SEQ ID NO:17);

(iii) F1: RSDNLRE (SEQ ID NO:26);

F2: NNTQLIE (SEQ ID NO:27);

F3: TSSILSR (SEQ ID NO:28);

F4 RSDNLSA (SEQ ID NO:29); and

F5: RKDTRIT (SEQ ID NO:30); and

(iv) F1: RSDNLSV (SEQ ID NO:19);

F2: QNATRIN (SEQ ID NO:15);

F3: RSDNLST (SEQ ID NO:20) or RSDHLSQ (SEQ ID NO:24);

F4: QSATRTK (SEQ ID NO:21);

F5 RSDNLSR (SEQ ID NO:22); and

F6: RNDNRKT (SEQ ID NO:23);

wherein the first and second zinc finger nucleases cleave and inactivate the endogenous cellular FUT8 gene in the isolated cell; and

introducing an exogenous sequence encoding an antibody into the cell, wherein the antibody is produced in the isolated cell.

2. The method of claim 1 , wherein the first and second zinc finger nucleases are encoded by the same nucleic acid.

3. The method of claim 1 , wherein the first and second zinc finger nucleases are encoded by different nucleic acids.

4. The method of claim 1 , wherein the cleavage domains are wild-type FokI cleavage domain.

5. The method of claim 1 , wherein at least one of the cleavage domains is an engineered FokI cleavage domain.

6. The method of claim 1 , wherein the exogenous sequence is integrated into the inactivated FUT8 gene.

7. The method of claim 1 , further comprising inactivating an endogenous glutamine synthetase (GS) gene in the isolated cell.

8. A cell or cell line for producing an antibody, wherein the cell or cell line is produced by the method of claim 1 .

9. The cell or cell line of claim 8 , wherein the cell is a mammalian cell or cell line selected from the group consisting of a COS cell, a CHO cell, a VERO cell, a MDCK cell, a WI38 cell, a V79 cell, a B14AF28-G3 cell, a BHK cell, a HaK cell, a NS0 cell, a SP2/0-Ag14 cell, a HeLa cell, an HEK293 cell, and a perC6 cell.

10. The cell or cell line of claim 8 , wherein one or more additional genes are partially or fully inactivated.

11. The cell or cell line of claim 10 , wherein glutamine synthetase (GS) is inactivated.

Assignments (1)
CHANGE OF NAME Recorded Nov 6, 2017
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 044383/0799 →
Continuity (6)
Continuation 14289459 · May 28, 2014
Division 12931265 · Jan 27, 2011
Division 12218035 · Jul 10, 2008
Provisional Application 60959202 · Jul 12, 2007
Provisional Application 60993624 · Sep 13, 2007
Related Publication 20160194665A1 · Jul 7, 2016